{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-041606","form_type":"8-K","ticker":"GRCE","cik":"0001444192","company_name":"Grace Therapeutics, Inc.","filed_at":"2023-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.938924+00:00","generated_at":"2026-06-11T14:08:07.043724+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Acasti Pharma Q1 net loss $4.0M; FDA aligned on Phase 3 GTX-104 trial; cash runway to Q2 2025","bullets":["Net loss $4.0M ($0.54 per share) vs $4.5M ($0.61 per share) year ago.","Cash and equivalents $21.6M at quarter end; projected runway through Q2 2025 covering potential GTX-104 NDA submission.","FDA alignment on STRIVE-ON Phase 3 safety trial for GTX-104; first patient dosing expected Q4 2023.","R&D expenses fell to $1.1M from $2.3M on restructuring; $1.5M severance costs incurred.","Appointed new CMO, VP Clinical Operations, VP Program Management; expanded Scientific Advisory Board with three key opinion leaders."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-041606","json":"https://secwatch.observer/filing/0000950170-23-041606.json","markdown":"https://secwatch.observer/filing/0000950170-23-041606.md","text":"https://secwatch.observer/filing/0000950170-23-041606.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1444192/000095017023041606/0000950170-23-041606-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1444192/000095017023041606/acst-20230811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T14:08:07.043724+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ec36a6a3b031edcbde113bc361cc4ded6433586e","claim":"Grace Therapeutics, Inc. reported fiscal quarter ended June 30, 2023 results: net income $4.0 million, EPS $0.54 per share.","evidence_excerpt":"Acasti Pharma Inc. issued a press release announcing its financial results for the fiscal quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1444192/000095017023041606/0000950170-23-041606-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal quarter ended June 30, 2023"},{"label":"Net income","value":"$4.0 million"},{"label":"EPS","value":"$0.54 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}